Cytokinetics
CYTK
484 hedge funds and large institutions have $13.7B invested in Cytokinetics in 2026 Q2 according to their latest regulatory filings, with 94 funds opening new positions, 237 increasing their positions, 103 reducing their positions, and 47 closing their positions.
487% more call options, than puts
Call options by funds: $630M | Put options by funds: $107M
130% more repeat investments, than reductions
Existing positions increased: 237 | Existing positions reduced: 103
100% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 47
42% more capital invested
Capital invested by funds: $9.63B → $13.7B (+$4.03B)
10% more funds holding
Funds holding: 441 → 484 (+43)
9.34% more ownership
Funds ownership: 119.56% → 128.89% (+9.3%)
6% less funds holding in top 10
Funds holding in top 10: 16 → 15 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$255M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$120M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$108M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$85.8M |
| 5 |
Holocene Advisors
New York
|
+$82.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$409M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$97.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$77.4M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$65.1M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$57.7M |
CYTK Hedge Fund Activity: Q2 2026 in Review
484 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2026, worth a combined $13.7B — up 42% from $9.63B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new CYTK positions and 47 closed out — a net gain of 47 holders — while 237 added to existing stakes and 103 trimmed.
The largest buyer was BlackRock, adding an estimated $255M. The largest seller was Fidelity Investments, cutting an estimated $409M.
- 484 institutional investors held Cytokinetics (CYTK) as of Q2 2026, up from 441 in Q1 2026.
- Funds reported $13.7B of Cytokinetics stock for Q2 2026, up 42% quarter-over-quarter.
- 94 funds opened new Cytokinetics positions in Q2 2026 and 47 closed out, a net change of +47 holders.
- The largest Cytokinetics buyer in Q2 2026 was BlackRock, an estimated $255M added.
- The largest Cytokinetics seller in Q2 2026 was Fidelity Investments, an estimated $409M sold.
Based on aggregated 13F filings for Q2 2026.